Washington, D.C. (PRWEB) February 01, 2012
In response to a study conducted at the University of North Carolina/Chapel Hill, as reported by the Associated Press, that questions the effectiveness of proton beam radiation therapy for the treatment of prostate cancer, the National Association for Proton Therapy (NAPT) found the released abstract to be unremarkable and missing definitive data for physicians and prostate patients to make an informed decision regarding the best treatment option.
The full study, to be presented later this week at a poster session of the American Society of Clinical Oncology (ASCO) meeting in San Francisco, clearly was not meant to be definitive as noted in the AP story.
"It is an "observational study" requiring a more definitive approach as stated by the federal Agency for Healthcare Research and Quality (AHRQ). We look forward to seeing more data, and we are convinced that more rigorous studies will prove the over-all benefits of proton therapy for the treatment of prostate cancer," said Leonard Arzt, executive director of NAPT.
The NAPT is confident that come this fall at the American Society of Therapeutic Radiation and Oncology (ASTRO) meeting, clinicians and patients will learn about encouraging new studies underway validating the clinical benefits of proton therapy in treating prostate cancer. The proton community is committed to comparative effectiveness studies (CER) across the entire spectrum of prostate cancer treatment modalities.